Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 71Prostatic Neoplasms 67Neoplasm Metastasis 56Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 45Multiple Myeloma 44Colorectal Neoplasms 41Pancreatic Neoplasms 37Myelodysplastic Syndromes 35Carcinoma, Renal Cell 33Ovarian Neoplasms 31Melanoma 30Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Glioblastoma 27Triple Negative Breast Neoplasms 26Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 24Lymphoma 23Burkitt Lymphoma 22Squamous Cell Carcinoma of Head and Neck 21Glioma 20Fallopian Tube Neoplasms 20Carcinoma, Hepatocellular 18Mouth Neoplasms 17Leukemia, Biphenotypic, Acute 17Brain Neoplasms 17Sarcoma 16Oropharyngeal Neoplasms 16

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sinonasal Squamous Cell Carcinoma × Specimen Handling × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡